RT Book, Section A1 LoVecchio, Frank A2 Tintinalli, Judith E. A2 Ma, O. John A2 Yealy, Donald M. A2 Meckler, Garth D. A2 Stapczynski, J. Stephan A2 Cline, David M. A2 Thomas, Stephen H. SR Print(0) ID 1166599754 T1 Monoamine Oxidase Inhibitors T2 Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9e YR 2020 FD 2020 PB McGraw-Hill Education PP New York, NY SN 9781260019933 LK accessmedicine.mhmedical.com/content.aspx?aid=1166599754 RD 2024/03/28 AB Monoamine oxidase inhibitors (MAOIs) were the first class of antidepressants, but current use of these agents is primarily limited to treating atypical and refractory cases of depression (Table 179-1).1 Newer antidepressants have a more favorable side effect profile, less overdose toxicity, and no dietary restrictions. The declining popularity of oral MAOIs for the treatment of depression is partially offset by their increasing use for the treatment of Parkinson’s disease.2 In addition, a transdermal method of selegiline administration, approved for use in major depression, appears to avoid some of the worrisome aspects associated with traditional oral therapy.3-5